Comparison of Denosumab and Zoledronic Acid in Postmenopausal Women With Osteoporosis: Bone Mineral Density (BMD) and Trabecular Bone Score (TBS)

BACKGROUND: Denosumab (DEN) and zoledronic acid (ZOL) currently represent the most potent antiresorptive agents for the treatment of osteoporosis. Despite similar effects on bone resorption, these agents have distinct mechanisms of action. The objective of this study was to compare the effect of DEN...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Taewook, Park, Si Young, Lee, Soon Hyuck, Park, Jong Hoon, Suh, Seung Woo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980365/
https://www.ncbi.nlm.nih.gov/pubmed/35380023
http://dx.doi.org/10.3346/jkms.2022.37.e68

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980365/
https://www.ncbi.nlm.nih.gov/pubmed/35380023
http://dx.doi.org/10.3346/jkms.2022.37.e68

Ejemplares similares